Want to see JP:8095 full AI Analyst Report?
8095 Stock Chart & Stats
¥483.00
-¥7.00(-1.48%)
At close: 4:00 PM EST
¥483.00
-¥7.00(-1.48%)
Day’s Range― - ―
52-Week Range¥456.00 - ¥541.00
Previous CloseN/A
Volume111.30K
Average Volume (3M)270.46K
Market Cap
¥20.90B
Enterprise Value¥33.32B
Total Cash (Recent Filing)¥10.19B
Total Debt (Recent Filing)¥22.65B
Price to Earnings (P/E)8.9
Beta0.68
Next Earnings
Oct 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.54%
Share Statistics
EPS (TTM)54.24
Shares Outstanding41,182,423
10 Day Avg. Volume280,330
30 Day Avg. Volume270,463
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.70
Price to Sales (P/S)0.30
P/FCF Ratio37.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Margins & Return To ProfitA steady expansion in gross margin to ~35% and a return to positive net income in 2025 indicate structural improvements in procurement, pricing or mix. Sustained margin recovery increases durable operating leverage, improving cash generation potential and resilience versus revenue cyclicality.
Consistent Revenue GrowthConsistent, positive top-line growth (including a rebound in 2024 and 2025 growth) reflects steady end-market demand for pharmaceutical distribution. Durable revenue expansion supports scale benefits in logistics and purchasing, aiding margin sustainability over the medium term.
Defensive Distribution Business ModelA core pharma distribution and logistics model supplies recurring demand from pharmacies and medical channels. This creates predictable volumes and long-term customer relationships, underpinning steady cash flows and competitiveness through service/scale advantages in warehousing and delivery.
Bears Say
Volatile Cash GenerationIrregular operating cash conversion and recurring negative free cash flow in several years point to working-capital swings or heavy reinvestment needs. Persistent cash volatility limits the company's ability to deleverage, fund growth, or sustain dividends without external financing.
Higher Leverage In 2025An increase in debt in 2025 tightens financial flexibility amid earnings variability. Higher leverage raises refinancing and interest-rate risk, constrains capacity for opportunistic investment, and amplifies downside if operating performance softens over the medium term.
Earnings Volatility And Past LossLarge swings from profit to sizable loss (2024) demonstrate execution and earnings instability. Such volatility undermines predictability for capital allocation, makes long-term planning harder, and can erode investor and creditor confidence if profitability does not remain consistently positive.
Astena Holdings Co.,Ltd. News
8095 FAQ
What was Astena Holdings Co.,Ltd.’s price range in the past 12 months?
Astena Holdings Co.,Ltd. lowest stock price was ¥456.00 and its highest was ¥541.00 in the past 12 months.
What is Astena Holdings Co.,Ltd.’s market cap?
Astena Holdings Co.,Ltd.’s market cap is ¥20.90B.
When is Astena Holdings Co.,Ltd.’s upcoming earnings report date?
Astena Holdings Co.,Ltd.’s upcoming earnings report date is Oct 09, 2026 which is in 71 days.
How were Astena Holdings Co.,Ltd.’s earnings last quarter?
Astena Holdings Co.,Ltd. released its earnings results on Jul 13, 2026. The company reported ¥20.58 earnings per share for the quarter, beating the consensus estimate of N/A by ¥20.58.
Is Astena Holdings Co.,Ltd. overvalued?
According to Wall Street analysts Astena Holdings Co.,Ltd.’s price is currently Overvalued.
Does Astena Holdings Co.,Ltd. pay dividends?
Astena Holdings Co.,Ltd. pays a Semiannually dividend of ¥9 which represents an annual dividend yield of 3.54%. See more information on Astena Holdings Co.,Ltd. dividends here
What is Astena Holdings Co.,Ltd.’s EPS estimate?
Astena Holdings Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Astena Holdings Co.,Ltd. have?
Astena Holdings Co.,Ltd. has 41,182,423 shares outstanding.
What happened to Astena Holdings Co.,Ltd.’s price movement after its last earnings report?
Astena Holdings Co.,Ltd. reported an EPS of ¥20.58 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.762%.
Which hedge fund is a major shareholder of Astena Holdings Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:8095
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astena Holdings Co.,Ltd.
Astena Holdings Co., Ltd., a Japanese company founded in 1914 and based in Chuo, is engaged in the development and distribution of a wide array of healthcare and chemical products. Its Fine Chemical division specializes in manufacturing and selling active pharmaceutical ingredients (APIs) and vital medical supplies used in treatments for fever reduction, pain relief, inflammation management, and blood vessel constriction. The Medical division focuses on biotechnology-related activities, providing support services for drug development and distributing essential medical equipment. The Health & Beauty Care, and Food segment is responsible for marketing non-prescription medications, raw materials for food and functional food products, and cosmetic ingredients. This division also manages direct-to-consumer sales through online and mail-order platforms, alongside offering contract manufacturing services for cosmetic items. Additionally, Astena Holdings' Industrial Chemicals division produces and supplies specialized chemicals for surface treatment and other industrial applications, serving sectors such as printed circuit boards, electronic devices, general plating processes, and semiconductors. The company, initially known as Iwaki & Co., Ltd., officially adopted the name Astena Holdings Co., Ltd. in June 2021.
Technical Analysis
Pharmarise Holdings Corp.
―
Ohki Health Care Holdings, Inc.
―
Medical System Network Co., Ltd.
―
Tsubota Laboratory Incorporated
―
Chordia Therapeutics Inc.
―